Monopar Therapeutics CEO Robinson sells $1.17 million in stock

Published 05/04/2025, 00:30
Monopar Therapeutics CEO Robinson sells $1.17 million in stock

Chandler Robinson, the Chief Executive Officer of Monopar Therapeutics (NASDAQ:MNPR), recently sold 33,334 shares of the company’s common stock. The shares were sold on April 2 at a weighted average price of $35 per share, amounting to a total transaction value of approximately $1.17 million. The sale comes amid a significant -25% decline in the stock price over the past week, though InvestingPro data shows the stock has delivered an impressive 840% return over the past year. Following this transaction, Robinson holds 822,255 shares in the company. The sale was part of a series of transactions executed by Tactic Pharma LLC, where Robinson holds a managerial position along with other members. With a current market capitalization of $177 million and analyst price targets ranging from $40 to $76, InvestingPro subscribers can access 8 additional key insights about MNPR’s valuation and financial health.

In other recent news, Monopar Therapeutics announced its fourth quarter and full-year 2024 financial results, leading Jones Trading to downgrade the stock from a Buy to a Hold rating. This decision reflects a recalibration of expectations based on the earnings report and adjusted timelines for key drug developments. Meanwhile, Piper Sandler initiated coverage of Monopar with an Overweight rating and set a price target of $76 per share, citing optimism about the potential of ALXN1840 for treating Wilson disease. Piper Sandler also highlighted Monopar’s ongoing work on a therapy targeting uPAR for solid tumors, indicating potential growth prospects for the company. In executive news, Monopar appointed Quan Vu as the new Chief Financial Officer, bringing extensive experience in corporate finance and strategy. Furthermore, Lavina Talukdar joined Monopar’s Board of Directors, bringing over two decades of experience in healthcare investments and financial strategy. These developments come as Monopar continues to advance its therapeutic programs and navigate the regulatory landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.